How should we use calcineurin inhibitors in myasthenia gravis?

Hiroyuki Murai

Research output: Contribution to journalReview articlepeer-review


Calcineurin inhibitors are approved for the treatment of myasthenia gravis in Japan. Utsugisawa et al. described the use of calcineurin inhibitors and outcomes of myasthenia gravis in Japan using the data of a multicenter survey. According to the result, they argue that calcineurin inhibitors should be given more aggressively to late-onset myasthenia gravis patients and early-stage disease.

Original languageEnglish
Pages (from-to)118-119
Number of pages2
JournalClinical and Experimental Neuroimmunology
Issue number2
Publication statusPublished - May 1 2015

All Science Journal Classification (ASJC) codes

  • Neuroscience (miscellaneous)
  • Immunology
  • Immunology and Microbiology (miscellaneous)
  • Clinical Neurology


Dive into the research topics of 'How should we use calcineurin inhibitors in myasthenia gravis?'. Together they form a unique fingerprint.

Cite this